Flovent HFA Related Published Studies
Well-designed clinical trials related to Flovent HFA (Fluticasone Inhalation)
Long-term monotherapy with suplatast tosilate in patients with mild atopic asthma: a pilot comparison with low-dose inhaled fluticasone. [2011.06]
Efficacy and safety of fluticasone and formoterol in a single pressurized metered dose inhaler. [2011.05]
Comparative lung bioavailability of fluticasone/salmeterol via a breath-actuated spacer and conventional plastic spacers. [2011.04]
Difference between patient-reported side effects of ciclesonide versus fluticasone propionate. [2010.12]
Prolonged protection of the new inhaled corticosteroid fluticasone furoate against AMP hyperresponsiveness in patients with asthma. [2010.12]
Combination therapy salmeterol/fluticasone versus doubling dose of fluticasone in children with asthma. [2010.11.15]
The effect of inhaled salmeterol, alone and in combination with fluticasone propionate, on management of COPD patients. [2010.10]
Montelukast added to fluticasone propionate does not alter inflammation or outcomes. [2010.10]
Inhaled fluticasone propionate reduces postoperative sore throat, cough, and hoarseness. [2010.10]
Population pharmacokinetics and pharmacodynamics of inhaled ciclesonide and fluticasone propionate in patients with persistent asthma. [2010.10]
Effect of fluticasone on markers of inflammation and quality of life in steroid-naive patients with mild asthma. [2010.01]
Adding montelukast to fluticasone propionate/salmeterol for control of asthma and seasonal allergic rhinitis. [2010.01]
Fixed or adjustable maintenance-dose budesonide/formoterol compared with fixed maintenance-dose salmeterol/fluticasone propionate in asthma patients aged >or=16 years: post hoc analysis of a randomized, double-blind/open-label extension, parallel-group study. [2010]
Treatment comparison of budesonide/formoterol with salmeterol/fluticasone propionate in adults aged > or =16 years with asthma: post hoc analysis of a randomized, double-blind study. [2010]
Population pharmacokinetics and pharmacodynamics of inhaled ciclesonide and
fluticasone propionate in patients with persistent asthma. [2010]
Additional effects of pranlukast in salmeterol/fluticasone combination therapy for the asthmatic distal airway in a randomized crossover study. [2009.12]
Salmeterol/fluticasone propionate vs. double dose fluticasone propionate on lung function and asthma control in children. [2009.12]
Add-on salmeterol compared to double dose fluticasone in pediatric asthma: a double-blind, randomized trial (VIAPAED). [2009.11]
The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. [2009.10.31]
Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial. [2009.10.20]
Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes. [2009.10]
Benefits of low-dose inhaled fluticasone on airway response and inflammation in mild asthma. [2009.10]
A novel breath-actuated integrated vortex spacer device increases relative lung bioavailability of fluticasone/salmeterol in combination. [2009.08]
Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD. [2009.08]
Fluticasone propionate/salmeterol and exercise-induced asthma in children with persistent asthma. [2009.05]
Effects of fluticasone propionate and salmeterol hydrofluoroalkane inhalation aerosol on asthma-related quality of life. [2009.04]
Anti-inflammatory effects of salmeterol/fluticasone, tiotropium/fluticasone or tiotropium in COPD. [2009.04]
Effect of inhaled fluticasone on lung function in infants with recurrent wheezing: a randomised controlled trial. [2009.03]
In vivo comparison of the relative systemic bioavailability of fluticasone propionate from three anti-static spacers and a metered dose inhaler. [2009.02]
Preemptive use of high-dose fluticasone for virus-induced wheezing in young children. [2009.01.22]
Bronchodilator reversibility, airway eosinophilia and anti-inflammatory effects of inhaled fluticasone in COPD are not related. [2008.11]
Effects of inhaled fluticasone propionate on CTLA-4-positive CD4+CD25+ cells in induced sputum in mild asthmatics. [2008.11]
[Combination of inhaled salmeterol/fluticasone and tiotropium in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial.] [2008.11]
Effectiveness of high repeated doses of inhaled budesonide or fluticasone in controlling acute asthma exacerbations in young children. [2008.09]
Efficacy and tolerability of salmeterol/fluticasone propionate versus montelukast in childhood asthma: A prospective, randomized, double-blind, double-dummy, parallel-group study. [2008.08]
Comparison of salmeterol/fluticasone propionate (FP) combination with FP+sustained release theophylline in moderate asthma patients. [2008.07]
The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. [2008.06.01]
Comparison of adjustable- and fixed-dose budesonide/formoterol pressurized metered-dose inhaler and fixed-dose fluticasone propionate/salmeterol dry powder inhaler in asthma patients. [2008.06]
Comparison of the anti-inflammatory effects of extra-fine hydrofluoroalkane-beclomethasone vs fluticasone dry powder inhaler on exhaled inflammatory markers in childhood asthma. [2008.06]
Tiotropium and salmeterol/fluticasone combination do not cause oxygen desaturation in COPD. [2008.06]
Fluticasone propionate protects against ozone-induced airway inflammation and modified immune cell activation markers in healthy volunteers. [2008.06]
Breath-synchronized plume-control inhaler for pulmonary delivery of fluticasone propionate. [2008.05.22]
Early bronchodilatory effects of budesonide/formoterol pMDI compared with fluticasone/salmeterol DPI and albuterol pMDI: 2 randomized controlled trials in adults with persistent asthma previously treated with inhaled corticosteroids. [2008.05]
Fluticasone furoate nasal spray: effective monotherapy for symptoms of perennial allergic rhinitis in adults/adolescents. [2008.05]
Comparison of mometasone furoate dry powder inhaler and fluticasone propionate dry powder inhaler in patients with moderate to severe persistent asthma requiring high-dose inhaled corticosteroid therapy: findings from a noninferiority trial. [2008.04]
Efficacy and safety of fluticasone propionate/salmeterol 250/50mcg Diskus administered once daily. [2008.04]
Efficacy of fluticasone metered-dose inhaler and dry powder inhaler for pediatric asthma. [2008.02]
The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. [2008.01.01]
Systemic exposure and urinary cortisol effects of fluticasone propionate formulated with hydrofluoroalkane in 4- to 11-year-olds with asthma. [2008.01]
Endocrine and immunologic effects of inhaled fluticasone propionate in healthy dogs. [2008.01]
Salmeterol/Fluticasone Propionate via Diskustrade mark Once Daily versus Fluticasone Propionate Twice Daily in Patients with Mild Asthma not Previously Receiving Maintenance Corticosteroids. [2008]
Comparable spirometric efficacy of tiotropium compared with salmeterol plus fluticasone in patients with COPD: a pilot study. [2008]
The Efficacy and Safety of Combination Salmeterol (50 {micro}g)/Fluticasone Propionate (500 {micro}g) Inhalation Twice Daily Via Accuhaler in Chinese Patients With COPD. [2007.12]
Anti-inflammatory effects of high-dose inhaled fluticasone versus oral prednisone in asthma exacerbations. [2007.12]
Comparison of add-on therapy to inhaled fluticasone propionate in children with asthma: residual volume and exhaled nitric oxide as outcome measures. [2007.11]
Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial. [2007.11]
Plasma concentrations of fluticasone propionate and budesonide following inhalation: effect of induced bronchoconstriction. [2007.10]
Intranasal ciclesonide coadministration with inhaled fluticasone propionate-salmeterol does not suppress cortisol in allergic rhinitis patients. [2007.09]
Fast onset of effect of budesonide/formoterol versus salmeterol/fluticasone and salbutamol in patients with chronic obstructive pulmonary disease and reversible airway obstruction. [2007.09]
A randomized study comparing ciclesonide and fluticasone propionate in patients with moderate persistent asthma. [2007.08]
Salmeterol/fluticasone stable-dose treatment compared with formoterol/budesonide adjustable maintenance dosing: impact on health-related quality of life. [2007.07.04]
Beclometasone dipropionate extrafine aerosol versus fluticasone propionate in children with asthma. [2007.07]
The influence of fluticasone inhalation on markers of carcinogenesis in bronchial epithelium. [2007.05.15]
Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. [2007.04.17]
Adherence with montelukast or fluticasone in a long-term clinical trial: results from the mild asthma montelukast versus inhaled corticosteroid trial. [2007.04]
Effects of inhaled fluticasone on angiogenesis and vascular endothelial growth factor in asthma. [2007.04]
Potency ratio fluticasone propionate (Flixotide Diskus)/budesonide (Pulmicort Turbuhaler). [2007.03]
Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. [2007.02.22]
Comparative evaluation of the leukotriene receptor antagonist pranlukast versus the steroid inhalant fluticasone in the therapy of aged patients with mild bronchial asthma. [2007]
Combination therapy with the single inhaler salmeterol/fluticasone propionate versus increased doses of inhaled corticosteroids in patients with asthma. [2007]
Doppler echocardiographic assessment of the effects of inhaled long-acting beta2-agonists on pulmonary artery pressure in COPD patients. [2007]
Efficacy and safety of fluticasone propionate hydrofluoroalkane inhalation aerosol in pre-school-age children with asthma: a randomized, double-blind, placebo-controlled study. [2006.11]
A comparative study of inhaled ciclesonide 160 microg/day and fluticasone propionate 176 microg/day in children with asthma. [2006.10]
Usefulness of HFA-BDP for adult patients with bronchial asthma: randomized crossover study with fluticasone. [2006.09]
Duration of action of the salmeterol/fluticasone combination inhaler administered in the evening: a randomized controlled trial in childhood asthma. [2006.09]
Secondary prevention of asthma by the use of Inhaled Fluticasone propionate in Wheezy INfants (IFWIN): double-blind, randomised, controlled study. [2006.08.26]
High-dose inhaled fluticasone does not replace oral prednisolone in children with mild to moderate acute asthma. [2006.08]
Estimating the cost-effectiveness of fluticasone propionate for treating chronic obstructive pulmonary disease in the presence of missing data. [2006.07]
Bronchial responsiveness to leukotriene D4 is resistant to inhaled fluticasone propionate. [2006.07]
Comparison of three valved holding chambers for the delivery of fluticasone propionate-HFA to an infant face model. [2006.06]
Comparison of fluticasone propionate aqueous nasal spray and oral montelukast for the treatment of seasonal allergic rhinitis symptoms. [2006.06]
Effects of intranasal fluticasone and salmeterol on allergen-induced nasal responses. [2006.06]
Effects of levocetirizine as add-on therapy to fluticasone in seasonal allergic rhinitis. [2006.05]
Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. [2006.04.01]
Asthma control can be maintained when fluticasone propionate/salmeterol in a single inhaler is stepped down. [2006.03]
Can inhaled fluticasone alone or in combination with salmeterol reduce systemic inflammation in chronic obstructive pulmonary disease? Study protocol for a randomized controlled trial [NCT00120978]. [2006.02.06]
Non-viral wheezing in preschool children: the effect of inhaled fluticasone on symptoms and lung function. [2006.02]
Efficacy and tolerability of fluticasone propionate/salmeterol administered twice daily via hydrofluoroalkane 134a metered-dose inhaler in adolescent and adult patients with persistent asthma: a randomized, double-blind, placebo-controlled, 12-week study. [2006.01]
Fluticasone propionate hydrofluoroalkane inhalation aerosol in patients receiving inhaled corticosteroids. [2006.01]
Control of mild to moderate asthma over 1-year with the combination of salmeterol and fluticasone propionate. [2006.01]
Inhaled fluticasone propionate is effective as well as oral prednisone in reducing sputum eosinophilia during exacerbations of asthma which do not require hospitalization. [2006]
Additional clinical benefit of enoxaparin in COPD patients receiving salmeterol and fluticasone propionate in combination. [2006]
Minimal tolerance to the bronchoprotective effect of inhaled salmeterol/fluticasone combination on allergene challenge. [2006]
Fluticasone Propionate HFA-134a Pressurized Metered-Dose Inhaler in Adolescents and Adults with Moderate to Severe Asthma. [2005.12]
Co-administration of salbutamol and fluticasone for emergency treatment of children with moderate acute asthma. [2005.11]
The efficacy and safety of fluticasone propionate in very young children with persistent asthma symptoms. [2005.11]
Fluticasone propionate nasal spray is superior to montelukast for allergic rhinitis while neither affects overall asthma control. [2005.10]
Once-daily administration of fluticasone propionate does not worsen controlled airway hyperresponsiveness in patients with asthma. [2005.09]
Comparative efficacy and safety of low-dose fluticasone propionate and montelukast in children with persistent asthma. [2005.08]
Montelukast, compared with fluticasone, for control of asthma among 6- to 14-year-old patients with mild asthma: the MOSAIC study. [2005.08]
Efficacy and safety of salmeterol/fluticasone propionate delivered via a hydrofluoroalkane metered dose inhaler in Chinese patients with moderate asthma poorly controlled with inhaled corticosteroids. [2005.07]
|
